Bremen, May 25, 2023 - MeVis Medical Solutions AG [ISIN: DE000A0LBFE4], a leading medical imaging software company, today announced its results for the first half of fiscal year 2022/2023, reporting period October 1, 2022 to March 31, 2023.
In the first half of fiscal year 2022/2023, the Company's revenues amounted to € 8,472 k (prev. year: € 8,546 k). Of these revenues, 26 % (prev. year: 26 %) were attributable to the sale of licenses, 35 % (prev. year: 30 %) to maintenance revenues, and 39 % (prev. year: 44 %) to other revenues, which include, among other things, services for and recharges to affiliated companies and the parent company.
Earnings before interest and taxes (EBIT) fell from € 3,421 k to € 1,839 k, mainly as a result of the year-on-year increase in personnel expenses and higher expenses for foreign currency translation, corresponding to an EBIT margin of 22 %.
Income from long-term loans amounted to € 624 k (previous year: € 85 k) and was attributable to interest income from the loan granted to Varex Imaging Deutschland AG, for which an interest rate adjustment was made at the beginning of the financial year. This results in earnings before taxes (EBT) of € 1,893 k (prev. year: € 3,463 k).
Income taxes of € 64 k (prev. year: € 42 k) were incurred in the past half-year. Therefore, taking into account the expense from the profit to be transferred to Varex Imaging Deutschland AG of € 1,829 k (prev. year: € 3,421 k), the net profit for the year amounts to € 0 k (prev. year: € 0 k).
At this point in time, we are maintaining our forecast: sales for fiscal year 2022/2023 are now expected to be almost stable compared to the previous year at € 18.0 million to € 18.5 million. In addition to sales with the customer Hologic, only slightly increasing sales revenues are expected in the lung and liver area. We expect a decline in the area of development services. For earnings before interest and taxes (EBIT), we expect a decline to between € 4.5 million to € 5.0 million. The forecast stability in sales and the simultaneous increase in personnel costs, in addition to a significant negative result from currency translation differences, is the main driver for the EBIT outlook.
As in the past reporting period, the Executive Board will regularly review its expectations in the course of fiscal 2022/2023 on the basis of current business performance.